The majority of these antibody drug candidates have entered clinical trials for cancer treatment [20], while Catumaxomab (trade name Removab), a trifunctional bispecific mAb [16, 21], was approved in the European Union (EU) in April 2009 for intraperitoneal (i.p.)treatment of malignant ascites (MA) in patients with EpCAM-positive carcinomas. The gene discussed is EPCAM; the disease is cancer.